BriaCell Therapeutics announces 1-for-10 reverse stock split effective August 25, 2025 to maintain Nasdaq listing

BriaCell Therapeutics Corp.

Share consolidation of 1 post-split share for every 10 pre-split shares, effective August 25, 2025.
Post-consolidation common shares trade on Nasdaq (BCTX) and TSX (BCT) under same symbols.
Consolidation intended to ensure continued compliance with Nasdaq listing requirements.
No fractional shares issued; fractions less than 0.5 cancelled, 0.5 or greater rounded up to one share.
Outstanding convertible securities' exercise/conversion prices proportionately adjusted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.